O-1812

O-1812 is an analgesic compound which is a cannabinoid receptor agonist. It is a derivative of HHC which is a type of synthetic cannabinoid. It is specifically a selective agonist for the CB2 receptor, and was one of the first selective CB2 agonists to be discovered and researched.

Chemistry

O-1812 is a derivative of HHC, which is a type of synthetic cannabinoid. It is a selective agonist for the CB2 receptor, meaning it binds to this receptor and activates it. This is in contrast to a CB1 receptor antagonist, which would bind to the CB1 receptor but not activate it.

Pharmacology

The CB2 receptor is primarily found in the immune system, and its activation is associated with immune system modulation and anti-inflammatory effects. This makes O-1812 potentially useful for treating conditions such as chronic pain, inflammation, and autoimmune diseases. However, further research is needed to fully understand the potential therapeutic uses and side effects of O-1812.

Research

Research into O-1812 and other CB2 receptor agonists is ongoing. Early studies suggest that these compounds may have therapeutic potential in a variety of conditions, including chronic pain, inflammation, and autoimmune diseases. However, more research is needed to confirm these findings and to fully understand the potential risks and benefits of these compounds.

See also

• Cannabinoid receptor
• Cannabinoid receptor agonist
• HHC
• CB2 receptor
• Analgesic

O-1812 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia